These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 30526892)
1. The complications of vasculitis and its treatment. King C; Harper L; Little M Best Pract Res Clin Rheumatol; 2018 Feb; 32(1):125-136. PubMed ID: 30526892 [TBL] [Abstract][Full Text] [Related]
2. Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. Matraiah EH; Olisaka N; Philipos M; Walbaum D; Dospinescu P; Fluck N; Basu N; Kidder D Clin Rheumatol; 2018 Jul; 37(7):1991-1996. PubMed ID: 29808456 [TBL] [Abstract][Full Text] [Related]
3. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Nettleton E; Sattui SE; Wallace Z; Putman M Arthritis Care Res (Hoboken); 2024 Feb; 76(2):288-294. PubMed ID: 37643919 [TBL] [Abstract][Full Text] [Related]
7. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910 [TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis. Jones RB Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382 [TBL] [Abstract][Full Text] [Related]
9. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Lenert A; Lenert P Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919 [TBL] [Abstract][Full Text] [Related]
10. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Timlin H; Lee SM; Manno RL; Seo P; Geetha D Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088 [TBL] [Abstract][Full Text] [Related]
11. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial. Miloslavsky EM; Niles JL; Wallace ZS; Cortazar FB; Fernandes A; Laliberte K; Stone JH Semin Arthritis Rheum; 2018 Oct; 48(2):288-292. PubMed ID: 29530330 [TBL] [Abstract][Full Text] [Related]
12. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. Thery-Casari C; Euvrard R; Mainbourg S; Durupt S; Reynaud Q; Durieu I; Belot A; Lobbes H; Cabrera N; Lega JC Autoimmun Rev; 2020 May; 19(5):102505. PubMed ID: 32173512 [TBL] [Abstract][Full Text] [Related]
13. Rituximab for treatment of severe renal disease in ANCA associated vasculitis. Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment outcomes in pregnant patients with ANCA-associated vasculitides: A systematic review of literature. Singh P; Dhooria A; Rathi M; Agarwal R; Sharma K; Dhir V; Nada R; Minz R; Suri V; Jain S; Sharma A Int J Rheum Dis; 2018 Sep; 21(9):1734-1740. PubMed ID: 30345645 [TBL] [Abstract][Full Text] [Related]
15. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368 [TBL] [Abstract][Full Text] [Related]
16. Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why? Alba MA; Flores-Suárez LF Reumatol Clin; 2016; 12(1):39-46. PubMed ID: 26255570 [TBL] [Abstract][Full Text] [Related]
17. Management of ANCA associated vasculitis. Wallace ZS; Miloslavsky EM BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597 [TBL] [Abstract][Full Text] [Related]
18. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR; N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198 [TBL] [Abstract][Full Text] [Related]
19. Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective. Haris Á; Dolgos S; Polner K Int Urol Nephrol; 2017 Jan; 49(1):91-102. PubMed ID: 27671907 [TBL] [Abstract][Full Text] [Related]
20. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients? Tesar V; Hruskova Z Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]